rican population [J ]. Journal of the National Cancer Institute,2012,104(7) :556-565.[15] Hong D,Y e F,Lu W,et a l.Methylation status of the long controlregion of H P V 16 in clinical cervical specimens [J ]. MolecularMedicine Reports,2008,1 (4) ：555 -560.[16] Xi L F，Jiang M J,Shen Z P，et a l.Inverse association between methylation of human papillomavirus type 16 D N A and risk of cervicalintraepithelial neoplasia grades 2 or 3 [J ]. PLoS O n e,2011,6(8)：e23897.[17] Yang HJ. Aberrant D N A methylation in cervical carcinogenesis[J]. Chinese Journal of Cancer,2013 ,32( 1) ：42 -48.[18] Park IS,Chang X,Loyo M,et a l.Characterization of the methylation patterns in human papillomavirus type 16 viral D N A in headand neck cancers [J]. Cancer Prevention Research, 2011,4(2)：207 -217.[19] Badal V,Chuang LS,Tan EH,et a l. C p G methylation of humanpapillomavirus type 16 D N A in cervical cancer cell lines and inclinical specimens ：Genomic hypomethylation correlates with carcinogenic progression [J ]. Journal of Virology, 2003,77 (11 )：6227 - 6234.[20] Piyathilake CJ,Macaluso M,Alvarez RD,et a l.A higher degree ofmethylation of the H P Y16 E6 gene i s associated with a lower likelihood of being diagnosed with cervical intraepithelial neoplasia[J].Cancer,2011,117(5) ：957 -963.[21 ]Hublarova P, Hrstka R, Rotterova P, et a l. Prediction of humanpapillomavirus 16 E6 gene expression and cervical intraepithelialneoplasia progression by methylation status [J ]. InternationalJournal of Gynecological Cancer,2009,19(3) ：321 —325.[22] Patel D A,Rozek L S,Colacino J A,et a l. Patterns of cellular andH P V16 methylation as biomarkers for cervical neoplasia [J ]. JVirol Methods,2012,184(1 -2)：84 -92.[23] Bryant D,Tristram A,Liloglou T,et a l. Quantitative measurementof human papillomavirus type 16 L1/L2 D N A methylation correlates with cervical disease grade [J ]. J Clin Virol,2014,59(1)：24 -29.[24] Zhong J,Agha G,BaccarelIi AA. The role of D N A methylation incardiovascular risk and disease ：Methodological aspects,study design, and data analysis for epidemiological studies[J]. CirculationResearch,2016,118(l) ：119-131.[25] Nawaz I,Qiu X,W u H,et a l.Development of a multiplex methylation specific P C R suitable for (early) detection of non —small celllung cancer[ J].Epigenetics,2014,9(8) ：1138 -1148.[26] Nyren P. Enzymatic method for continuous monitoring of D N A polymerase activity[J]. Analytical Biochemistry,1987,167 (2) ：235-238.[27] Steenbergen RDM,Snijders PJT,Heideman D A M,e t a l. Clinicalimplications of (epi) genetic changes in H P Y- induced cervicalprecancerous lesions [J]. Nat Rev Cancer ,2014,14(6) :395 -405. (编校：文玉洁）Chkl蛋白激酶及其抑制剂的研究进展袁会军、张秋菊\范钰S李晶晶、刘斌2Research progress of Chkl and its inhibitorYuan Huijun1,Zhang Qiuju1,Fan Y u1,Li Jingjing1,Liu Bin21 B a sic M e d ic a l C ollege o f G a n su U n iversity o f C hinese M e d ic in e,G a n su L a n zh o u 130000 9 C h in a-,2 P a th o lo g y D ep a rtm en t o f L a n zh o u G ene ra l H o sp ita l of L a n zh o u M ilita ry C o m m a n d f G a n su L a n zh o u730000 9C h in a.【Abstract】Chkl (checkpoint kinase 1) belongs to the serine/threonine protein kinase family,it i s a core protein ofthe cell cycle checkpoints in response to D N A damage. Many studies have shown that Chkl has the function of promoting tumor hypeiplasia,i t s lack of tumor cells can be more sensitive to radiotherapy or chemotherapy,and i t s inhibitorsand other molecular targeted drugs with the combination of "synthetic lethal" effect,so Chkl possible i s a new targetfor future tumor therapy. In this paper we will reviewed the Chkl and i t s role in tumor treatment.【K e y words】Chkl，D D R，cell cycle，inhibitor of ChklM o d e m Oncology 2018,26(17) ：2797 -2800【收稿日期】2018-01 -17【基金项目】甘肃省自然科学基金项目（编号:1508RJZA017)【作者单位】1甘肃中医药大学基础医学院病理教研室，甘肃兰州73_2解放军兰州总医院病理科，甘肃兰州730000【作者简介】袁会军(1983 -)，男，甘肃庆阳人，在读硕士，主治医师，主要从事乳腺肿瘤病理研究工作。
E-m a i l:81106396@qq.c〇m【通讯作者】刘斌(1963 -)，男，陕西白水人，博士，主任医师，主要从事肿瘤病理研究工作。
E-mail:liumb@ 189. cn【指示性摘要】Chkl(CheckP〇i n t kinase1，Chkl)属丝氨酸/苏氨酸蛋白激酶家族成员，在D N A损伤反应（D N A damage resp〇nse，D D R)中是细胞周期检测点的核心蛋白。
很多研究表明，Chkl蛋白激酶具有促进肿瘤细胞增 生的功能，它的缺乏能使肿瘤细胞对放疗或化疗更加敏感，且其抑制剂与其它分子靶向药物联合应用具有 “合成致死”的效应，因此Chkl可作为今后肿瘤治疗的新靶点。
本文就Chkl蛋白激酶及其在肿瘤治疗中的 作用作一综述。
【关键词】Chkl;D D R;细胞周期;Chkl抑制剂【中图分类号】R730.5 【文献标识码】A D O I：10. 3969/j.issn.1672 - 4992.2018.17.038【文章编号】1672 - 4992-(2018) 17 - 2797 - 04肿瘤传统的治疗方法有三种，即外科治疗、放射治疗和 化学治疗，它们有各自的适应证，虽无法相互替代，但可相互 结合。
